Clinical factors associated with initiation of and persistence with ADP receptor-inhibiting oral antiplatelet treatment after acute coronary syndrome: A nationwide cohort study from Finland

BMJ Open

Volumn 6, Issue 11, 2016, Pages

  Prami, Tuire ^a   Khanfir, Houssem ^a   Deleskog, Anna ^b   Hasvold, Pål ^b   Kytö, Ville ^c,d   Reissell, Eeva ^e   Airaksinen, Juhani ^c  

^a EPID Research Oy   (Finland)

^b ASTRAZENECA R AND D   (Sweden)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

drug utilization; oral antiplatelet; persistence; unstable angina pectoris

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; TICAGRELOR; UNCLASSIFIED DRUG; WARFARIN; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; AGED; ALZHEIMER DISEASE; ARTICLE; ATRIAL FIBRILLATION; COHORT ANALYSIS; CORONARY ARTERY BYPASS GRAFT; DEMENTIA; DRUG USE; FEMALE; FINLAND; GROUPS BY AGE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VERY ELDERLY; ANGINA PECTORIS; HEART INFARCTION; MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; FEMALE; FINLAND; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES;

EID: 84999115038     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-012604     Document Type: Article

References (30)

1. Jokhadar M, Jacobsen SJ, Reeder GS, et al. Sudden death and recurrent ischemic events after myocardial infarction in the community. Am J Epidemiol 2004;159:1040-6.
2. Koch MB, Davidsen M, Andersen LV, et al. Increasing prevalence despite decreasing incidence of ischaemic heart disease and myocardial infarction. A national register based perspective in Denmark, 1980-2009. Eur J Prev Cardiol 2015;22:189-95.
3. Vartiainen E, Laatikainen T, Peltonen M, et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010;39:504-18.
4. Kolandaivelu K, Leiden BB, OGara PT, et al. Non-Adherence to cardiovascular medications. Eur Heart J 2014;35:3267-76.
5. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
6. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
7. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
8. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
9. Steg PG, James SK, AtarD, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-619.
10. Dores H, Aguiar C, Ferreira J, et al. Compliance of pharmacological treatment for non-ST-elevation acute coronary syndromes with contemporary guidelines: influence on outcomes. Cardiovasc Diagn Ther 2014;4:13-20.
11. Roe MT, Parsons LS, Pollack CV, et al. Quality of care by classification of myocardial infarction: Treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 2005;165:1630-6.
12. Thim T, Johansen MB, Chisholm GE, et al. Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: An observational study. BMC Cardiovasc Disord 2014;14:100.
13. Roy P, Bonello L, Torguson R, et al. Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation. Am J Cardiol 2009;103:801-5.
14. The R Foundation. The R Project for Statistical Computing. http://www.r-project.org (accessed 19 Aug 2015).
15. ISPE. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008;17:200-8.
16. Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf 2016;25:2-10.
17. Bavishi C, Koulova A, Bangalore S, et al. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-Analysis of observational studies. Catheter Cardiovasc Interv 2016;88:E12-22.
18. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525-38.
19. Hvelplund A, Galatius S, Madsen M, et al. Significance of the invasive strategy after acute myocardial infarction on prognosis and secondary preventive medication: A nationwide study of 6364 women and 11, 915 men. J Invasive Cardiol 2012;24:19-24.
20. Shore S, Jones PG, Maddox TM, et al. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Heart 2015;101:800-7.
21. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-Term perspective. Eur Heart J 2015;36:1163-70.
22. Halvorsen S, Jortveit J, Hasvold P, et al. Initiation of and long-Term adherence to secondary preventive drugs after acute myocardial infarction. BMC Cardiovasc Disord 2016;16:115.
23. Green A, Pottegard A, Broe A, et al. Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: A Danish nationwide population-based cohort study. BMJ Open 2016;6:e010880.
24. Byrd JB, Maddox TM, ODonnell CI, et al. Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program. Am Heart J 2014;168:340-5.
25. Cruden NL, Din JN, Janssen C, et al. Delay in filling first clopidogrel prescription after coronary stenting is associated with an increased risk of death and myocardial infarction. J Am Heart Assoc 2014;3: e000669.
26. Specialised health care register-Quality description. National Institute for Health and Welfare. http://www.thl.fi/en/web/thlfi-en/statistics/information-on-statistics/quality-descriptions/specialised-health-care (accessed 09 Feb 2016).
27. Sund R. Quality of the Finnish hospital discharge register: A systematic review. Scand J Public Health 2012;40:505-15.
28. Al-Khadra S, Meisinger C, Amann U, et al. Secondary prevention medication after myocardial infarction: persistence in elderly people over the course of 1 year. Drugs Aging 2014;31:513-25.
29. Lenzi J, Rucci P, Castaldini I, et al. Does age modify the relationship between adherence to secondary prevention medications and mortality after acute myocardial infarction? A nested case-control study. Eur J Clin Pharmacol 2015;71:243-50.
30. Mathews R, Wang TY, Honeycutt E, et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. Am Heart J 2015;170:62-9. 10